Drug-mediated hyperemia

PreclinicalSmall molecule

FFundación EPIC

Drug-mediated hyperemia is one of 4 small molecule programs targeting Hyperemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperemiaActive, not recruiting

HyperemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Hyperemia

#DrugCompanyPhaseTrials

Lexiscan

Astellas

Phase 1

1 2

Adenocard

Astellas

Phase 1

1 3

Alphagan

AbbVie

Phase 1

—4

Drug-mediated hyperemia

FFundación EPIC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperemia1 trial

Treatment of Slow-flow After Primary Percutaneous Coronary Intervention With Flow-mediated Hyperemia

Completed·FFundación EPIC·N/A·NCT04685941·67 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Drug-mediated hyperemia. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Drug-mediated hyperemia compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Drug-mediated hyperemia. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fundación EPIC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFundación EPIC

Drug-mediated hyperemia

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyperemia1 trial

References

Drug Info

Quick Facts

Related News